Celgene Overview

  • Founded

  • 1986

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 8,800

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $80.3B

Celgene General Information

Description

Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets drugs to treat multiple myeloma and a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma.

Contact Information

Website
www.celgene.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Bristol-Myers Squibb
Primary Office
  • 86 Morris Avenue
  • Summit, NJ 07901
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celgene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 20-Nov-2019 $80.3B 000.00 000.00 Completed Profitable
3. PIPE 000.00 Completed Profitable
2. IPO 28-Jul-1987 $12.7M $12.7M Completed Generating Revenue
1. Early Stage VC 01-Jan-1986 Completed Generating Revenue
To view Celgene’s complete valuation and funding history, request access »

Celgene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets d
Drug Discovery
Summit, NJ
8,800 As of 2021
000.00
00.00 0000-00-00
000000&0 000.00

00000

t. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
0.00 0000-00-00
00000000000 000.00

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupid
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celgene Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
00000 Corporation Basel, Switzerland 000000 00.000 00000000000 00.000
000000 000000 000 Private Equity-Backed Mumbai, India 0000 00000000000
000000 0000 000000 Formerly VC-backed Torrance, CA 00 000.00 000000000 - 000.00
You’re viewing 5 of 28 competitors. Get the full list »

Celgene Patents

  • 4,371

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 249

    Granted

  • 65

    Pending

  • 000

    Expiring in next 12 mo

Celgene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230028747-A1 Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases Pending 16-Jun-2021 0000000000
US-20220387405-A1 Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide Pending 06-May-2021 0000000000
US-20220401569-A1 Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) Pending 30-Apr-2021 00000000000
EP-4121051-A1 Combination therapy for acute myeloid leukemia Pending 12-Mar-2021
US-20220265618-A1 Methods of treating prostate cancer Pending 22-Feb-2021 A61K31/438
To view Celgene’s complete patent history, request access »

Celgene Board Members (21)

Name Representing Role Since
Hans Bishop Self Board Member 000 0000
Michael Casey Celgene Board Member 000 0000
Rodman Drake Celgene Board Member 000 0000
You’re viewing 3 of 21 board members. Get the full list »

Celgene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celgene Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asseily Ventures Venture Capital Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
Edelson Technology Partners Venture Capital Minority 000 0000 000000 0
Ridgeback Capital Venture Capital Minority 000 0000 000000 0
To view Celgene’s complete investors history, request access »

Celgene Investments & Acquisitions (127)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 07-Jan-2020 00000 0000 0000 Decision/Risk Analysis
0000000 20-Dec-2019 00000 0000 000.00 Drug Discovery
000000 000000 15-Oct-2019 00000 0000 000.00 Drug Discovery 00000 000
0000000 11-Sep-2019 00000 0000 000.00 Drug Discovery
RAPT Therapeutics 18-Jun-2019 Later Stage VC 0000 Drug Discovery
You’re viewing 5 of 127 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Celgene Subsidiaries (2)

Company Name Industry Location Founded
Acetylon Pharmaceuticals Drug Discovery Boston, MA 2008
0000000000000 Biotechnology Gaithersburg, MD 0000
To view Celgene’s complete subsidiaries history, request access »

Celgene Exits (70)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 20-Dec-2019 00000 00000 00 000.00 Completed
  • 16 buyers
000000 00000000000 15-Oct-2019 00000 00000 00 000.00 Completed
  • 6 buyers
0000 000000000000 18-Jun-2019 00000 00000 00 0000 Completed
  • 6 buyers
0000000000 10-May-2019 00000 0000 Completed
  • 2 buyers
Vividion Therapeutics 30-Apr-2019 Later Stage VC 0000 Completed
  • 12 buyers
You’re viewing 5 of 70 exits. Get the full list »